Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
- Patients with a mass in the pancreas suspicious for adenocarcinoma without biopsy
proven distant metastases.
- Patients who are scheduled for clinically indicated EUS
- Patients who are medically unfit for endoscopic sedation or surgery due to severe
comorbid disease such as uncontrolled coronary disease, or oxygen dependant pulmonary
- Patients who have any other malignancy other than basal cell carcinoma within the
past 5 years.
Type of Study:
Observational Model: Case-Only, Time Perspective: Prospective
To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.
Outcome Time Frame:
End of study
United States: Institutional Review Board
- Pancreatic Cancer
- Pancreatic Neoplasms
|Mayo Clinic||Jacksonville, Florida 32224|